2-[(3S)-6-[(1R,3Z,5Z)-2-methylidene-6-(1-oxa-8-azaspiro[4.5]decan-8-ylmethyl)-5-(trifluoromethyl)cyclonona-3,5-dien-1-yl]oxy-2,3-dihydro-1-benzofuran-3-yl]acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 2-[(3S)-6-[(1R,3Z,5Z)-2-methylidene-6-(1-oxa-8-azaspiro[4.5]decan-8-ylmethyl)-5-(trifluoromethyl)cyclonona-3,5-dien-1-yl]oxy-2,3-dihydro-1-benzofuran-3-yl]acetic acid
• 化学式: C₃₀H₃₆F₃NO₅
• 分子量: 547.6
• InChiKey: SHFQSNDWRJAHRF-YNJZYCNUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  68.2
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS<br/>[FR] NOUVEAUX ACIDES INDANYLOXYDIHYDROBENZOFURANYLACÉTIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014122067A1

  公开（公告）日：2014-08-14

  The present invention relates to compounds of general formula I, (I) wherein the group R1 is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR 1) and modulate its activity. The compounds are suitable for the treatment and prevention of diseases which can be influenced by this receptor; metabolic diseases, such as diabetes, more specifically type 2 diabetes mellitus, and conditions associated with the disease, including insulin resistance, obesity, cardiovascular disease and dyslipidemia.